NASDAQ:PMCB PharmaCyte Biotech (PMCB) Stock Price, News & Analysis $1.98 -0.04 (-1.98%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.98▼$1.9950-Day Range$1.95▼$2.2952-Week Range$1.76▼$2.82Volume1,735 shsAverage Volume21,253 shsMarket Capitalization$16.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestTrends Get PharmaCyte Biotech alerts: Email Address Ad Crypto 101 MediaBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.Click here to get The Crypto Bull Run Millionaire Blueprint now. About PharmaCyte Biotech Stock (NASDAQ:PMCB)PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.Read More PMCB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PMCB Stock News HeadlinesMay 21, 2024 | businesswire.comMyMD Pharmaceuticals Secures Strategic InvestmentsMay 21, 2024 | businesswire.comPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.December 18, 2023 | msn.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024December 15, 2023 | finance.yahoo.comCompanies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In GrowthDecember 5, 2023 | morningstar.comPharmaCyte Biotech Inc PMCBNovember 15, 2023 | markets.businessinsider.comPharmaCyte Biotech Invests In Femasys - Quick FactsNovember 15, 2023 | finance.yahoo.comFemasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte BiotechJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.June 15, 2023 | msn.comPharmaCyte completes tender offer to purchase sharesJune 15, 2023 | finance.yahoo.comPharmaCyte Biotech Announces Final Results of Tender OfferJune 14, 2023 | bizjournals.comLos Angeles Biotech NewsMay 11, 2023 | finance.yahoo.comPharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per ShareApril 21, 2023 | nasdaq.comBiotech ETFs’ Performance Deserves A LookApril 12, 2023 | fortune.com300 biotech and pharma CEOs including the head of Pfizer call for a reversal of the abortion pill banFebruary 2, 2023 | msn.comA 45-year-old biotech CEO may have reduced his biological age by at least 5 years through a rigorous medical program that can cost up to $2 million a year, Bloomberg reportedFebruary 2, 2023 | finance.yahoo.comPharmaCyte Biotech to Implement Second $10-Million Share Repurchase PlanOctober 7, 2022 | seekingalpha.comPharmaCyte to evaluate opportunities; CEO steps downSee More Headlines Receive PMCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings12/15/2021Today7/26/2024Next Earnings (Estimated)7/29/2024Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PMCB CUSIPN/A CIK1157075 Webpharmacyte.com Phone917-595-2850Fax917-595-2851Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-9.69% Return on Assets-5.86% Debt Debt-to-Equity RatioN/A Current Ratio8.16 Quick Ratio8.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.33 per share Price / Book0.46Miscellaneous Outstanding Shares8,450,000Free Float8,366,000Market Cap$16.74 million OptionableOptionable Beta-0.19 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Joshua N. Silverman (Age 54)Interim CEO, President & Director Comp: $197.92kMr. Carlos A. Trujillo CPA (Age 66)CPA, Chief Financial Officer Comp: $380kDr. Jose L. Iglesias M.D. (Age 67)Consulting Chief Medical Officer Dr. Hans-Peter HammesMember of Medical & Scientific Advisory Board and ConsultantKey CompetitorsJATT AcquisitionNYSE:JATTBioLineRxNASDAQ:BLRXMediciNovaNASDAQ:MNOVProPhase LabsNASDAQ:PRPHTurnstone BiologicsNASDAQ:TSBXView All CompetitorsInstitutional OwnershipK2 Principal Fund L.P.Bought 22,890 shares on 5/14/2024Ownership: 3.876%View All Institutional Transactions PMCB Stock Analysis - Frequently Asked Questions How have PMCB shares performed this year? PharmaCyte Biotech's stock was trading at $2.16 at the beginning of the year. Since then, PMCB stock has decreased by 8.3% and is now trading at $1.9811. View the best growth stocks for 2024 here. How were PharmaCyte Biotech's earnings last quarter? PharmaCyte Biotech, Inc. (NASDAQ:PMCB) released its quarterly earnings data on Wednesday, December, 15th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. How do I buy shares of PharmaCyte Biotech? Shares of PMCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PMCB) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
